Navigation Links
Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
Date:1/9/2009

VANCOUVER, Jan. 9 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic tests, announced today that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris(R)).

"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis. This new collaboration with the UKCCG group will allow Sirius Genomics to significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled. We are delighted to be working with the UKCCG group to further our progress towards the commercialization of our first product," commented Dr. Brad Popovich, President and CEO of Sirius Genomics.

"The collaboration with Sirius Genomics is in direct alignment with our objective to disseminate and promote understanding of functional genomics in the wider intensive care community," stated Professor Charles Hinds, one of the Principal Investigators of the UKCCG Group. "We are very excited to be working with Sirius Genomics on this new collaboration."

Financial terms of the agreement were not disclosed.

About UKCCG: www.ukccg-gains.org/index.htm

The UKCCG Group is a collaborative consortium composed of multiple investigators, collaborators and members throughout the United Kingdom representing more than 35 hospitals. The group's primary objective is to undertake clinical functional genomics research in the critically ill and to develop related collaborative, laboratory based research projects with scientific colleagues.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that excels at developing pharmacogenomic (PGx) tests that lead to better patient outcomes through personalized medicine. Sirius' business focus is on generating value through improving the safety and effectiveness of pharmaceutical compounds. The Company's expert medical and business team correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):